{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T23:41:44Z","timestamp":1791157304766,"version":"4.1.0"},"reference-count":49,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,8,15]]},"DOI":"10.1097\/tp.0b013e3182247ae2","type":"journal-article","created":{"date-parts":[[2011,7,26]],"date-time":"2011-07-26T04:26:05Z","timestamp":1311654365000},"page":"303-310","source":"Crossref","is-referenced-by-count":201,"title":["Lower Malignancy Rates in Renal Allograft Recipients Converted to Sirolimus-Based, Calcineurin Inhibitor-Free Immunotherapy: 24-Month Results From the CONVERT Trial"],"prefix":"10.1097","volume":"92","author":[{"given":"Josefina","family":"Alber\u00fa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Pascoe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep M.","family":"Campistol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco P.","family":"Schena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria del Carmen","family":"Rial","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Polinsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John F.","family":"Neylan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joan","family":"Korth-Bradley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Goldberg-Alberts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric S.","family":"Maller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-9-20210129","first-page":"72","article-title":"Handbook of kidney transplantation.","author":"Danovitch","year":"2004"},{"key":"R2-9-20210129","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1523-1755.2004.00741.x","article-title":"Risk of malignancy with long-term immunosuppression in renal transplant recipients.","volume":"66","author":"Agraharkar","year":"2004","journal-title":"Kidney Int"},{"key":"R3-9-20210129","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1016\/j.transproceed.2006.02.016","article-title":"De novo malignancies after kidney and liver transplantations: Experience on 582 consecutive cases.","volume":"38","author":"Baccarani","year":"2006","journal-title":"Transplant Proc"},{"key":"R4-9-20210129","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1097\/01.TP.0000108491.62935.DF","article-title":"Skin cancers in renal-transplant recipients occur more frequently than previously recognized in a temperate climate.","volume":"77","author":"Bordea","year":"2004","journal-title":"Transplantation"},{"key":"R5-9-20210129","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/j.transproceed.2005.01.008","article-title":"Twenty-five-year survival of living related kidney transplants: Thirty-five years' experience.","volume":"37","author":"Yoshimura","year":"2007","journal-title":"Transplant Proc"},{"key":"R6-9-20210129","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients.","volume":"4","author":"Bustami","year":"2004","journal-title":"Am J Transplant"},{"key":"R7-9-20210129","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1097\/01.tp.0000203554.54242.56","article-title":"Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: Characteristics, risk factors and prognosis.","volume":"81","author":"Caillard","year":"2006","journal-title":"Transplantation"},{"key":"R8-9-20210129","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.1016\/j.transproceed.2007.03.113","article-title":"Isolated primary pulmonary Kaposi's sarcoma in a renal transplant recipient: A case report.","volume":"39","author":"Ghorbani","year":"2007","journal-title":"Transplant Proc"},{"key":"R9-9-20210129","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1111\/j.1432-2277.2006.00330.x","article-title":"Post-transplant de novo malignancies in renal transplant recipients: The past and present.","volume":"19","author":"Kauffman","year":"2006","journal-title":"Transpl Int"},{"key":"R10-9-20210129","doi-asserted-by":"crossref","first-page":"2529","DOI":"10.1016\/j.transproceed.2005.06.064","article-title":"Malignancies after kidney transplantation.","volume":"37","author":"Rascente","year":"2005","journal-title":"Transplant Proc"},{"key":"R11-9-20210129","doi-asserted-by":"crossref","first-page":"3068","DOI":"10.1016\/j.transproceed.2005.07.046","article-title":"Malignancy in renal recipients.","volume":"37","author":"Samhan","year":"2005","journal-title":"Transplant Proc"},{"key":"R12-9-20210129","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.1097\/01.ASN.0000126194.77004.9B","article-title":"Malignancy in renal transplantation.","volume":"15","author":"Morath","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R13-9-20210129","doi-asserted-by":"crossref","first-page":"3065","DOI":"10.1016\/j.transproceed.2005.08.011","article-title":"Development of malignancy following living donor kidney transplantation.","volume":"37","author":"Nafar","year":"2005","journal-title":"Transplant Proc"},{"key":"R14-9-20210129","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1001\/jama.296.23.2823","article-title":"Cancer incidence before and after kidney transplantation.","volume":"296","author":"Vajdic","year":"2006","journal-title":"JAMA"},{"key":"R15-9-20210129","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1038\/sj.ki.5002154","article-title":"The janus face of immunosuppression\u2014de novo malignancy after renal transplantation: The experience of the Transplantation Center Munich.","volume":"71","author":"Wimmer","year":"2007","journal-title":"Kidney Int"},{"key":"R16-9-20210129","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1097\/CMR.0b013e3282f0c880","article-title":"No increase of melanoma after kidney transplantation in the northern part of The Netherlands.","volume":"17","author":"Bastiaannet","year":"2006","journal-title":"Melanoma Res"},{"key":"R17-9-20210129","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/j.transproceed.2006.12.026","article-title":"Conversion from a calcineurin inhibitor-based immunosuppressive regimen to everolimus in renal transplant recipients: Effect on renal function and proteinuria.","volume":"39","author":"Morales","year":"2007","journal-title":"Transplant Proc"},{"key":"R18-9-20210129","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1681\/ASN.2005090993","article-title":"Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation.","volume":"17","author":"Campistol","year":"2006","journal-title":"J Am Soc Nephrol"},{"key":"R19-9-20210129","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1136\/bmj.38569.471007.AE","article-title":"Tacrolimus versus ciclosporin as primary immunosuppression for kidney transplant recipients: Meta-analysis and meta-regression of randomised trial data.","volume":"331","author":"Webster","year":"2005","journal-title":"BMJ"},{"key":"R20-9-20210129","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1016\/j.transproceed.2007.05.046","article-title":"Conversion to rapamycin immunosuppression for malignancy after kidney transplantation: Case reports.","volume":"39","author":"Iaria","year":"2007","journal-title":"Transplant Proc"},{"key":"R21-9-20210129","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.transproceed.2006.01.019","article-title":"Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy.","volume":"38","author":"Yakupoglu","year":"2006","journal-title":"Transplant Proc"},{"key":"R22-9-20210129","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/j.1432-2277.2006.00388.x","article-title":"Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation.","volume":"19","author":"Barth","year":"2006","journal-title":"Transpl Int"},{"key":"R23-9-20210129","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.TP.0000184006.43152.8D","article-title":"Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies.","volume":"80","author":"Kauffman","year":"2005","journal-title":"Transplantation"},{"key":"R24-9-20210129","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1097\/01.ASN.0000113248.59077.76","article-title":"Long-term benefits with sirolimus-based therapy after early cyclosporine withdrawal.","volume":"15","author":"Kreis","year":"2004","journal-title":"J Am Soc Nephrol"},{"key":"R25-9-20210129","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1111\/j.1399-0012.2004.00188.x","article-title":"Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: Results from five multicenter studies.","volume":"18","author":"Mathew","year":"2004","journal-title":"Clin Transplant"},{"key":"R26-9-20210129","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/j.1399-3046.2005.00360.x","article-title":"Replacing calcineurin inhibitors with mTOR inhibitors in children.","volume":"9","author":"Sindhi","year":"2005","journal-title":"Pediatr Transplant"},{"key":"R27-9-20210129","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/j.1399-0012.2005.00275.x","article-title":"A prospective 3-yr evaluation of tacrolimus-based immunosuppressive therapy in immunological high risk renal allograft recipients.","volume":"19","author":"Zaltzman","year":"2005","journal-title":"Clin Transplant"},{"key":"R28-9-20210129","doi-asserted-by":"crossref","first-page":"9953","DOI":"10.1158\/0008-5472.CAN-05-0921","article-title":"Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.","volume":"65","author":"Amornphimoltham","year":"2005","journal-title":"Cancer Res"},{"key":"R29-9-20210129","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.phrs.2004.03.007","article-title":"mTOR: A protein kinase switching between life and death.","volume":"50","author":"Asnaghi","year":"2004","journal-title":"Pharmacol Res"},{"key":"R30-9-20210129","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1038\/sj.bjc.6602162","article-title":"Targeting the mammalian target of rapamycin (mTOR): A new approach to treating cancer.","volume":"91","author":"Chan","year":"2004","journal-title":"Br J Cancer"},{"key":"R31-9-20210129","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1471-2407-5-4","article-title":"Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: Impact on tumor recurrence and malignancy.","volume":"5","author":"Engl","year":"2005","journal-title":"BMC Cancer"},{"key":"R32-9-20210129","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1016\/j.transproceed.2005.03.072","article-title":"The influence of mycophenolate mofetil versus azathioprine and mycophenolic acid pharmacokinetics on the incidence of acute rejection and infectious complications after renal transplantation.","volume":"37","author":"Satoh","year":"2005","journal-title":"Transplant Proc"},{"key":"R33-9-20210129","doi-asserted-by":"crossref","first-page":"2961","DOI":"10.1111\/j.1600-6143.2005.01117.x","article-title":"Addition of MMF to dual immunosuppression does not increase the risk of malignant short-term death after liver transplantation.","volume":"5","author":"Lake","year":"2005","journal-title":"Am J Transplant"},{"key":"R34-9-20210129","doi-asserted-by":"crossref","first-page":"1940","DOI":"10.1097\/01.ASN.0000076844.59963.CF","article-title":"Immunosuppression minimization: Current and future trends in transplant immunosuppression.","volume":"14","author":"Vincenti","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"R35-9-20210129","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1097\/TP.0b013e3181927a41","article-title":"Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial.","volume":"87","author":"Schena","year":"2009","journal-title":"Transplantation"},{"key":"R36-9-20210129","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1523\/JNEUROSCI.3706-05.2006","article-title":"Inhibition of calcineurin by FK506 protects against polyglutamine-huntingtin toxicity through an increase of huntingtin phosphorylation at S421.","volume":"26","author":"Pardo","year":"2006","journal-title":"J Neurosci"},{"key":"R37-9-20210129","doi-asserted-by":"crossref","first-page":"3714","DOI":"10.1038\/sj.emboj.7601246","article-title":"Overexpression of c-myc in pancreatic cancer caused by ectopic activation of NFATc1 and the Ca2+\/calcineurin signaling pathway.","volume":"25","author":"Buchholz","year":"2006","journal-title":"EMBO J"},{"key":"R38-9-20210129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/med.2610140102","article-title":"Rapamycin: A novel immunosuppressive macrolide.","volume":"14","author":"Sehgal","year":"1994","journal-title":"Med Res Rev"},{"key":"R39-9-20210129","first-page":"295","article-title":"Inhibitors of mammalian target of rapamycin as novel antitumor agents: From bench to clinic.","volume":"3","author":"Huang","year":"2002","journal-title":"Curr Opin Invest Drugs"},{"key":"R40-9-20210129","doi-asserted-by":"crossref","first-page":"4715","DOI":"10.1158\/0008-5472.CAN-05-3830","article-title":"Survival signaling by Notch1: Mammalian target of rapamycin (mTOR)-dependent inhibition of p53.","volume":"66","author":"Mungamuri","year":"2006","journal-title":"Cancer Res"},{"key":"R41-9-20210129","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1158\/0008-5472.CAN-05-2447","article-title":"Mechanism by which mammalian target of rapamycin inhibitors sensitize multiple myeloma cells to dexamethasone-induced apoptosis.","volume":"66","author":"Yan","year":"2006","journal-title":"Cancer Res"},{"key":"R42-9-20210129","doi-asserted-by":"crossref","first-page":"36490","DOI":"10.1074\/jbc.M401208200","article-title":"Inhibition of mammalian target of rapamycin activates apoptosis signal-regulating kinase 1 signaling by suppressing protein phosphatase 5 activity.","volume":"279","author":"Huang","year":"2004","journal-title":"J Biol Chem"},{"key":"R43-9-20210129","doi-asserted-by":"crossref","first-page":"41685","DOI":"10.1074\/jbc.M301181200","article-title":"Vasopressin type 1A receptor up-regulation by cyclosporin A in vascular smooth muscle cells is mediated by superoxide.","volume":"278","author":"Krauskopf","year":"2003","journal-title":"J Biol Chem"},{"key":"R44-9-20210129","doi-asserted-by":"crossref","first-page":"23329","DOI":"10.1074\/jbc.M100989200","article-title":"Cyclosporin A inhibits inositol 1,4,5-trisphosphate-dependent Ca2+ signals by enhancing Ca2+ uptake into the endoplasmic reticulum and mitochondria.","volume":"276","author":"Soraya","year":"2001","journal-title":"J Biol Chem"},{"key":"R45-9-20210129","doi-asserted-by":"crossref","first-page":"15406","DOI":"10.1074\/jbc.M211293200","article-title":"Cyclosporin A prevents the hypoxic adaptation by activating hypoxia-inducible factor-1\u03b1 pro-564 hydroxylation.","volume":"278","author":"D'Angelo","year":"2003","journal-title":"J Biol Chem"},{"key":"R46-9-20210129","doi-asserted-by":"crossref","first-page":"1899","DOI":"10.1073\/pnas.042529199","article-title":"Regulation of the tyrosine kinase Itk by the peptidyl-prolyl isomerase cyclophilin A.","volume":"99","author":"Brazin","year":"2002","journal-title":"Proc Natl Acad Sci USA"},{"key":"R47-9-20210129","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1002\/jcb.10253","article-title":"Interaction of the retinoblastoma gene product, RB, with cyclophilin A negatively affects cyclosporin-inhibited NFAT signaling.","volume":"86","author":"Cui","year":"2002","journal-title":"J Cell Biochem"},{"key":"R48-9-20210129","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1097\/01.TP.0000074360.62032.39","article-title":"Long-term improvement in renal function with sirolimus after early cyclosporine withdrawal in renal transplant recipients: 2-year results of the Rapamune Maintenance Regimen Study.","volume":"76","author":"Oberbauer","year":"2003","journal-title":"Transplantation"},{"key":"R49-9-20210129","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1002\/sim.2335","article-title":"Confidence intervals for an exposure adjusted incidence rate difference with applications to clinical trials.","volume":"25","author":"Liu","year":"2006","journal-title":"Statist Med"}],"container-title":["Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00007890-201108150-00009","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T20:17:48Z","timestamp":1786047468000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00007890-201108150-00009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,8,15]]},"references-count":49,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011]]}},"URL":"https:\/\/doi.org\/10.1097\/tp.0b013e3182247ae2","relation":{},"ISSN":["0041-1337"],"issn-type":[{"value":"0041-1337","type":"print"}],"subject":[],"published":{"date-parts":[[2011,8,15]]}}}